BioCardia Q3 net loss narrows to $2.6M; CardiAMP HF trial paused after DSMB review

BioCardia, Inc.

Q3 2023 revenue $357K (up 68% YoY); net loss $2.6M improves from $3.1M YoY.
DSMB recommended pause of CardiAMP HF trial; management agrees primary endpoint unlikely with current design.
Subset analysis: NT-proBNP>500 patients showed 59% relative risk reduction in mortality (p=0.028).
Company submitted new protocol (CardiAMP HF II) to FDA targeting responders; Japan PMDA consultation set for Nov 21.
Cash used in operations $2.4M; anticipates two Helix licensing/development partnerships in Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.89

BioCardia, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 8, 2023, BioCardia, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

BioCardia, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-030940

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.